Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Felice Musicco1, Ruggero Lasala2, Fiorenzo Santoleri3

  • 1Farmacia Ospedaliera, Irccs Istituto Nazionale Tumori Regina Elena e Istituto Dermatologico San Gallicano, Roma.

Recenti Progressi in Medicina
|November 17, 2024
PubMed
Summary

Time to treatment discontinuation (Ttd) is a key metric for oncology drugs. Real-world data shows third-generation anti-EGFR drugs significantly extend Ttd in non-small cell lung cancer (NSCLC) compared to older generations.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Impact of deep learning image reconstruction on ADC quantification and histogram metrics: a phantom study.

European radiology experimental·2026
Same author

Characteristics and Outcomes of Progressive Multifocal Leukoencephalopathy in Hematologic Malignancies: A SEIFEM Retrospective Review.

American journal of hematology·2026
Same author

Artificial Intelligence in Prostate MRI: Comparison of an AI-Based Software and an Experienced Radiologist for Detecting Clinically Significant Prostate Cancer.

Current oncology (Toronto, Ont.)·2026
Same author

Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2026
Same author

Daratumumab in the Treatment of Multiple Myeloma: Real World Evidence (2018-2024) at the a. Gemelli Polyclinic (Rome) and Comparison With Registration Studies.

Hospital pharmacy·2026

Area of Science:

  • Oncology
  • Pharmacoeconomics
  • Real-world evidence